Please log in to view this page
Username
Password
ACTG A5324 is a phase IV randomized, double-blinded, placebo-controlled study to assess the efficacy of adding Maraviroc (MVC)...
A5314 is a phase II randomized, double-blind, placebo-controlled 36-week trial that will examine the safety and efficacy of...
The investigators are looking for a better way to prevent cervical cancer. This study is comparing two different methods to...
We will address our hypothesis using a case-control study design. We plan to leverage the existing biorepository of...
This purpose of this study is to evaluate the pharmacokinetics (PK), safety, and tolerability of bedaquiline (BDQ) in...
